## ALNY: Alnylam Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -8.1% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($362.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. A look at Alnylam Pharmaceuticals (ALNY) valuation after Nasdaq 100 inclusion and convertible notes repurchase**
- Source: Simply Wall Street | 20251214T091009 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) recently joined the Nasdaq 100 and repurchased some 2027 convertible notes, impacting its visibility and capital structure. Despite recent share price cooling, the company shows strong long-term momentum with significant year-to-date and 5-year returns. While currently trading at a discount to consensus targets and considered 19.3% undervalued based on TTR revenue scaling, its price-to-sales ratio is higher than industry averages, suggesting potential valuation risk.

**2. Alnylam (ALNY) and Seagate (STX) Join Nasdaq 100 Index**
- Source: GuruFocus | 20251213T140832 | Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (ALNY) and Seagate Technology Holdings (STX) are set to join the Nasdaq 100 Index as part of its annual reconstitution, effective December 22, 2025. This inclusion is significant as major index funds like the Invesco QQQ Trust Series 1 ETF will adjust holdings, impacting the companies involved. Alnylam, a leader in RNA interference therapeutics, has a market capitalization of $52.52 billion and shows robust revenue growth but also a high debt-to-equity ratio and notable insider selling.

**3. Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027**
- Source: BioSpace | 20251212T110931 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals announced it has entered into agreements to repurchase approximately $34.4 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2027 for an estimated total cost of $51.9 million. Following these repurchases, which are expected to close shortly after a measurement period ending December 11, 2025, about $362.8 million of the Notes will remain outstanding. The company's previously established capped call transactions are expected to stay in effect.

**4. Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027**
- Source: Business Wire | 20251211T211009 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals, Inc. announced it has entered into agreements to repurchase approximately $34.4 million aggregate principal amount of its 1.00% Convertible Senior Notes due 2027 for about $51.9 million. Following these repurchases, which are subject to a price adjustment based on stock performance and customary closing conditions, approximately $362.8 million notes will remain outstanding. The company's capped call transactions related to the notes will remain in effect.

**5. Alnylam to repurchase $34.4 million of convertible notes**
- Source: Investing.com | 20251211T130950 | Somewhat-Bullish | Relevance: 100%
- Alnylam Pharmaceuticals (NASDAQ:ALNY) announced an agreement to repurchase approximately $34.4 million of its 1.00% Convertible Senior Notes due 2027 for about $51.9 million, including accrued interest. Following the repurchase, $362.8 million of these Notes will remain outstanding. The company, which specializes in RNA interference therapeutics, maintains a strong financial position with a current ratio of 2.54 and recently reported impressive revenue growth and profitability.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Stifel | $508 | $495 | +3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Stifel | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 7 ($0.03M) |
| Sells | 9 ($1.84M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 64.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- FMR, LLC: 12.7% (+6.1%)
- Capital World Invest: 12.4% (-2.2%)
- Vanguard Group Inc: 10.3% (+2.0%)
- Blackrock Inc.: 7.5% (-0.8%)
- JPMORGAN CHASE & CO: 6.9% (+340.7%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.6% 5d) with bearish MACD, trend may be turning.
2. Near-term weakness: 12.2% below SMA50 despite long-term uptrend.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Forward P/E 37.5x attractive for 114% earnings growth. Quality metrics strong (ROE 33%). Balance sheet: strong liquidity (2.5x). Revenue growth strong at 43% YoY. Insider selling cluster ($1.8M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $52.5B |
| Beta | 0.30 |
| 52W Range | $205.87 - $495.55 |
| Short Interest | 3.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.49 |
| Forward P/E | 37.5 |
| Current P/E | 80.1 |
| YoY Growth | 113.8% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -5.5% to -8.1% (-2.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.1pp (needs >3.0% for momentum thesis). Underperforming sector by 7.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). MACD histogram bearish (-5.70), momentum weakening. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -8.05% (CS: 1) | Weak |
| RSI_14 | 32.8 | Neutral |
| MACD Histogram | -5.70 | Bearish |
| vs SMA20 | 0.898x | Below |
| vs SMA50 | 0.878x | Below |
| vs SMA200 | 1.099x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $397.55
- **Stop Loss:** $362.29 (8.9% risk)
- **Target:** $432.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 28
- **Position Value:** $11,131.40
- **Portfolio %:** 11.13%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-12 (Est: $1.73)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.75 | $2.90 | +66.1% |
| 2025Q2 | $0.15 | $0.32 | +119.6% |
| 2025Q1 | $-0.37 | $-0.01 | +97.3% |
| 2024Q4 | $-0.14 | $0.06 | +142.5% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*